Date:3/4/2010

SAN DIEGO, March 4 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce its fourth quarter and year ended December 31, 2009 financial results on Tuesday, March 9, 2010 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 730-5769 (domestic) or (857) 350-1593 (international), participant
'/>"/>

SOURCE Orexigen Therapeutics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
2. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
3. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
4. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
6. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
7. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
8. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
9. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
10. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
11. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)